News
Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 ...
Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently ...
EMERYVILLE, Calif. (AP) — EMERYVILLE, Calif. (AP) — XOMA Royalty Corporation (XOMA) on Wednesday reported second-quarter net income of $9.2 million. On a per-share basis, the Emeryville, ...
Key Points Revenue (GAAP) beat estimates by 39.5% in Q2 2025, rising to $13.1 million on substantial milestone receipts. Recurring royalty income remained modest, with only $2.6 million from ...
Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) ("XOMA Royalty" or ...
Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, ...
Schrödinger announced it will discontinue clinical development of the CDC7 inhibitor SGR-2921 for acute myeloid leukemia (AML) and myelodysplastic syndromes following two patient deaths in an ...
NasdaqGM:XOMA 1 Year Share Price vs Fair Value Explore XOMA Royalty's Fair Values from the Community and select ...
23h
TipRanks on MSNLAVA Therapeutics Announces Acquisition by XOMA Corporation
LAVA Therapeutics ( ($LVTX) ) has issued an announcement. On August 13, 2025, LAVA Therapeutics announced its acquisition by XOMA Royalty ...
Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA's two partnered assets and unp ...
1d
TipRanks on MSNXoma Corp. Reports Strong Earnings Growth in 2025
Xoma Corp. ( ($XOMA) ) has released its Q2 earnings. Here is a breakdown of the information Xoma Corp. presented to its investors. Xoma Corp., a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results